Inspire Medical: Positive Spin Overlooks Deep-Seated Challenges and Execution Risks

What happened

Inspire Medical's stock has suffered a ~52% decline over the past year, driven by a sharp 2025 guidance cut that reset revenue growth from ~28% to ~12-13% due to GLP-1 competition and Inspire V rollout issues. Management has since stabilized by reaffirming the $900-910M revenue range and raising full-year EPS guidance to $0.90-1.00 through cost control, while maintaining mid-80s gross margins and a strong net cash position. A recent Zacks article touts strong Q4 results and R&D investments, but this glosses over the structural headwinds from GLP-1 therapies, which continue to pressure procedure volumes, and an ongoing DOJ investigation that adds regulatory uncertainty. The upcoming 2026 Medicare reimbursement uplift offers a potential tailwind by improving hospital economics, yet its benefit hinges on flawless execution and whether providers, not Inspire, capture the value. Despite the derated price at ~55x trailing EPS, the company remains a single-product franchise with high volatility, requiring investors to balance the promise of recovery against persistent competitive and operational risks.

Implication

The stock's steep decline has likely priced in near-term pessimism, creating a speculative entry point for those betting on a recovery fueled by the 2026 Medicare uplift and Inspire V adoption. However, GLP-1 therapies pose a durable threat to volume growth, demanding vigilant monitoring of procedure trends and patient conversion rates. The reimbursement boost could enhance margins, but it must translate into sustained volume increases without being eroded by payer pushback or competitive pricing. Management's ability to execute on the Inspire V transition and maintain cost discipline is critical for achieving double-digit revenue growth and EPS expansion toward the low-$2s by 2026. With elevated valuation multiples and concentrated risk, any misstep on these fronts could trigger further declines, necessitating cautious position sizing and active risk management.

Thesis delta

The investment thesis remains unchanged: Inspire is a potential buy for risk-tolerant investors seeking upside from reimbursement tailwinds and execution improvements, but it faces unaltered risks from GLP-1 competition and regulatory scrutiny. The Zacks article adds no new material information, merely repackaging the growth narrative without addressing the deeper challenges outlined in the DeepValue report.